Targeted Nanocarrier Combination Based Therapy for Lung Cancer

研究项目1-靶向纳米载体联合治疗肺癌-DR 曼迪普·萨奇德娃：非裔美国人的肺癌发病率比白人高50%。非洲裔美国人的癌症发病率和死亡率是美国所有种族/少数族裔群体中最高的。此外，非洲裔和白人美国妇女的癌症发病率继续稳步上升。非裔美国人肺癌的年龄调整死亡率为12%。NSCLC推荐的一线化疗是以铂为基础的联合化疗。尽管最近在化疗方面取得了进展，但非小细胞肺癌的有效率仍为50%，而且化疗也与不良反应有关。这就需要研究具有强大的抗癌活性和较低副作用的化疗方案，以改善肺癌的治疗结果。诺斯卡因(Nos)。一种抗微管剂，已被证明具有良好的抗癌活性。 我们的实验室已经证明，在H460移植瘤模型中，口服一氧化氮合酶显著地以剂量依赖的方式抑制肿瘤的生长。由于广泛的首过代谢和较差的生物利用度，NO的使用受到了限制。因此，利用可绕过首过效应(包被甘露糖胺)的纳米载体给药系统提高NO的口服生物利用度，并与化疗药物联合应用，发挥协同抗肿瘤作用，是治疗肺癌的一种新途径。

Research Project 1- Targeted Nanocarrier Combination Based Therapy for Lung Cancer - Dr. Mandip Sachdeva: Lung cancer incidence rate in African American is 50% higher than that of white Americans. African Americans have the highest cancer incidence and mortality rates of any racial/ethnic minority group in the U.S. Furthermore, its incidence continues to steadily rise among both African and white American women. The age adjusted death rate among African American population from lung cancer was found to be 12%. The recommended first line of chemotherapy In NSCLC is platinum based combination chemotherapy. Despite recent advances in chemotherapy, response rates in NSCLC remain <50% and also chemotherapy is associated with adverse effects. This necessitates investigation on chemotherapeutic options having potent anticancer activity and lower side effects to improve therapeutic outcomes in treatment of lung cancer. Noscapine (Nos). an antimicrotubular agent, has been shown to have promising anticancer activity. Our laboratory has already demonstrated that oral administration of Nos significantiy regress tumor growth in dose dependent manner in H460 xenograft tumor model. The use of Nos has been limited due to extensive first pass metabolism and poor bioavailability. Therefore, enhancing oral bioavailability of Nos using nanocarrier delivery system which can bypass the first pass effect (coated with mannosamine) and delivering in combination with chemotherapeutic agents to exert synergistic antitumor activity is a novel approach in treatment of lung cancer.